London’s FTSE 100 index slipped into negative territory as ongoing tensions across the Middle East continued to unsettle investor sentiment and dampen appetite for risk assets.
AstraZeneca, one of the index’s most heavily weighted constituents, acted as a significant drag on the broader benchmark during the session.
The pharmaceutical giant’s decline weighed disproportionately on the index given its substantial market capitalisation relative to other listed companies.
Geopolitical uncertainty in the Middle East has remained a persistent concern for traders in recent weeks, adding volatility across global equity markets and commodities.
Energy prices have been sensitive to the regional tensions, with fluctuations in crude oil feeding through to broader market movements and affecting sentiment on the London exchange.
The FTSE 100 is home to several major energy and defence companies, meaning shifts in geopolitical risk can have an outsized impact on the index compared with other global benchmarks.
Investors have been carefully monitoring diplomatic developments and any signals from governments or international bodies that might indicate a de-escalation in hostilities.
The mood across European markets more broadly has been cautious, with traders reluctant to take on significant positions until there is greater clarity over the geopolitical outlook.
Currency movements have also played a role, with sterling fluctuations adding another layer of complexity for internationally exposed companies listed on the London exchange.
AstraZeneca’s share price movement reflects a combination of sector-specific pressures and the wider risk-off environment that has characterised trading in recent sessions.
The blue-chip index remains sensitive to global macro developments, and analysts expect continued volatility as long as Middle East tensions show no clear signs of resolution.
Market participants will be watching closely for any corporate updates or macroeconomic data releases that could shift the mood and provide fresh direction for the FTSE 100.